Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer

AstraZeneca

AstraZeneca AB

AstraZeneca clinical programs — 249 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
EMA registrant Type
Company details
Status
Public
HQ
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
Employees
79,242
Programs
249
Drugs
238
Patents
2
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

AstraZeneca projects

249 ClinicalTrials.gov programs sponsored by AstraZeneca.

AstraZeneca has 249 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

249 programs

Clinical programs

Page 2 of 6

  1. D6974C00001

    AstraZeneca AB

    Primary Aldosteronism defined by excess aldosterone secretion

    phase 3 small molecule active

    1 trial

  2. D7000C00001

    AstraZeneca AB

    COVID-19

    phase 3 small molecule active

    1 trial

  3. D7025C00001

    AstraZeneca AB

    Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma or muscle invasive gallbladder cancer GBC)

    phase 3 small molecule active

    1 trial

  4. D7029C00001

    AstraZeneca AB

    Advanced Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  5. D702AC00001

    AstraZeneca AB

    HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

    phase 3 small molecule active

    1 trial

  6. D702BC00001

    AstraZeneca AB

    Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

    phase 3 small molecule active

    1 trial

  7. D702FC00001

    AstraZeneca AB

    Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

    phase 3 small molecule active

    1 trial

  8. D702GC00001

    AstraZeneca AB

    Lung Cancer

    phase 3 small molecule active

    1 trial

  9. D702NC00001

    AstraZeneca AB

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  10. D7310C00001

    AstraZeneca AB

    Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor

    phase 3 small molecule active

    1 trial

  11. D7402C00001

    AstraZeneca AB

    Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  12. D7632C00001

    AstraZeneca AB

    Locally-advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

  13. D781PC00001

    AstraZeneca AB

    Advanced HER2-expressing Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  14. D7984C00002

    AstraZeneca AB

    Locally advanced cervical cancer

    phase 3 small molecule active

    1 trial

  15. D7988C00001

    AstraZeneca AB

    Unresectable Pleural Mesothelioma

    phase 3 small molecule active

    1 trial

  16. D798AC00001

    AstraZeneca AB

    Metastatic Non-Small Cell Lung Cancer (mNSCLC)

    phase 3 small molecule active

    1 trial

  17. D8220C00027

    AstraZeneca AB

    Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  18. D8311C00001

    AstraZeneca AB

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  19. D8532C00001

    AstraZeneca AB

    Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  20. D8534C00001

    AstraZeneca AB

    Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  21. D8535C00001

    AstraZeneca AB

    ER+/HER2- Early Breast Cancer

    phase 3 small molecule active

    1 trial

  22. D8610C00001

    AstraZeneca AB

    Respiratory Syncytial Virus and Human Metapneumovirus

    phase 3 small molecule active

    1 trial

  23. D8991C00001

    AstraZeneca AB

    Advanced Platinum-resistant Epithelial Ovarian Cancer

    phase 3 small molecule active

    1 trial

  24. D9075C00001

    AstraZeneca AB

    The target population of interest in this study is participants with locally advanced (Stage III), unresectable NSCLC, whose tumours express PD L1 TC ≥ 1% as assessed by a central reference laboratory using the VENTANA PD-L1 (SP263) IHC assay, and who did not progress after definitive platinum based cCRT.

    phase 3 small molecule active

    1 trial

  25. D9078C00001

    AstraZeneca AB

    Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  26. D9103C00001

    AstraZeneca AB

    Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation

    phase 3 small molecule active

    1 trial

  27. D9106C00001

    AstraZeneca AB

    Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB; either squamous or non-squamous).

    phase 3 small molecule active

    1 trial

  28. D910DC00001

    AstraZeneca AB

    Histologically or cytologically confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (resection or ablation)

    phase 3 small molecule active

    1 trial

  29. D910GC00001

    AstraZeneca AB

    Histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).

    phase 3 small molecule active

    1 trial

  30. D910PC00001 - Volga

    AstraZeneca AB

    Bladder Cancer

    phase 3 small molecule active

    1 trial

  31. D910SC00001/KUNLUN

    AstraZeneca AB

    Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  32. D910VC00001

    AstraZeneca AB

    Locoregional Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  33. D9180C00003

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  34. D9180C00004

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  35. D9180C00012

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  36. D9180C00015

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 other active

    1 trial

  37. D9268C00001

    AstraZeneca AB

    "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"

    phase 3 small molecule active

    1 trial

  38. D926PC00001

    AstraZeneca AB

    Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  39. D926QC00001

    AstraZeneca AB

    Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  40. D926TC00001

    AstraZeneca AB

    Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-positive result or high-risk pathological feature

    phase 3 small molecule active

    1 trial

  41. D9311C00001

    AstraZeneca AB

    Endometrial Cancer

    phase 3 small molecule active

    1 trial

  42. D933AC00001

    AstraZeneca AB

    First-line patients with advanced biliary tract cancers (BTC)

    phase 3 small molecule active

    1 trial

  43. D933QC00001

    AstraZeneca AB

    Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)

    phase 3 small molecule active

    1 trial

  44. D933SC00001

    AstraZeneca AB

    Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  45. D9481C00001

    AstraZeneca AB

    Hyperkalaemia

    phase 3 small molecule active

    1 trial

  46. D9604C00001

    AstraZeneca AB

    Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.

    phase 3 small molecule active

    1 trial

  47. D9612C09998

    AstraZeneca AB

    Erosive Esophagitis

    phase 3 small molecule active

    1 trial

  48. D9670C00001

    AstraZeneca AB

    HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does AstraZeneca have?

249 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.